Associated Papers
Expanding the Molecular Characterization of Adenoid Ameloblastoma by Assessing a Panel of Oncogenes and Tumor Suppressor Genes.
Fonseca YG et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2026
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review.
Abujamous L et al.
The Oncologist, 2025
40665690 (PubMed )
Supplement: oyaf205_supplementary_data.zip › SupplementaryTable3.xlsx › SupplementaryTable3
Prevalence and breakdown of KRAS driver mutations in a large UK non-small cell lung cancer cohort.
Niesner ICC et al.
Journal of Clinical Pathology, 2025
Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance.
Faulkner LG et al.
Cancer Investigation, 2025
A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis.
Debouki-Joudi S et al.
Breast Disease, 2024
Genetic Analysis and Targeted Therapy Using Buparlisib and MK2206 in a Patient with Triple Metachronous Cancers of the Kidney, Prostate, and Squamous Cell Carcinoma of the Lung: A Case Report.
Zhao T et al.
Oncotargets and Therapy, 2021
Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing.
Oliveira DM et al.
Oncotarget, 2018
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA et al.
Hematology/oncology and Stem Cell Therapy, 2014
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Beaufort CM et al.
Plos One, 2014
25230021 (PubMed )
Supplement: pone.0103988.s007.xlsx › paper_mutation_table
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Santarpia L et al.
The Journal of Clinical Endocrinology and Metabolism, 2008
Select a paper to view details